The presence of Foxp3 + regulatory CD4 + T cells in tumor lesions is considered one of the major causes of ineffective immune response in cancer. It is not clear whether intratumoral T reg cells represent T reg cells pre-existing in healthy mice, or arise from tumor-specific effector CD4
Introduction
The observation that tumor antigen-specific B and T cells are activated in the course of tumor growth led to the presumption that augmenting the immune system function will lead to the eradication of tumor cells [1] . A multitude of cancer vaccines were designed to harness potent effector functions and exquisite specificity of the immune system to combat cancer. However, immunotherapy protocols used so far have had only a limited success what was attributed to poor recruitment of antigen specific T cells into tumor lesions, inadequate stimulation by antigens derived from tumor cells causing T cell anergy instead of T cell activation and, in particular, to the presence of regulatory T cells (T reg ) expressing a transcription factor Foxp3 [2] [3] [4] . Despite their importance for cancer immunity, the origin of T reg cells in tumors remains little known. Foxp3 + T reg cells are a specific population of CD4 + T lymphocytes that control normal immune homeostasis and selftolerance [5] . T reg cells were identified as the major obstacle to effective antitumor immunotherapy [6] [7] [8] . The abundance of these cells in peripheral blood is increased in patients with multiple types of cancer and their prevalence among tumor-infiltrating lymphocytes correlated with poor clinical prognosis [9] [10] [11] . In contrast, removal or inactivation of T reg cells led to enhanced antitumor immune response and better efficacy of cancer vaccines [12] [13] [14] [15] .
Two major subsets of Foxp3 + T reg cells, natural and adaptive T reg cells, were defined based on whether their suppressor function is acquired during normal T cell development in the thymus or following TCR stimulation in peripheral tissues or in vitro [16, 17] . The lack of appropriate surface markers so far precluded the analysis of the contribution of these subsets to the peripheral pool of regulatory cells in healthy and tumor-bearing mice expressing diverse, polyclonal TCR repertoire. Though the suppressor function of the two T reg subsets was found similar in in vitro tests, little is known how different are their homing properties, antigen specificities and the ability to expand in vivo in response to antigen stimulation and cytokines. The recent evidence that natural and adaptive T reg subsets have different gene expression signature and synergize to establish peripheral tolerance suggests that they serve non-redundant functions [18, 19] . In a recent report we have shown that the level of Foxp3 expression and TCR repertoires define two subsets of T reg cells in peripheral lymphoid organs [20] . The dominant fraction of peripheral T reg cells consistently expresses high level of Foxp3 and a characteristic set of TCRs not utilized by naive effector CD4 + T cells. The second T reg subset expressing low level of Foxp3, CD25 and GITR and constituting only a small fraction of T reg cells, could up-or downregulate Foxp3 when stimulated with antigen and utilized TCRs shared with naive T cells. The modulation of Foxp3 expression was dependent on the presence of cytokines, especially TGF-b, that increased the fraction of cells upregulating Foxp3. This T reg subset was able to efficiently expand in lymphopenic mice and in mice undergoing immune response to antigen where it became a major population of antigen-specific T reg cells. Since TCR repertoires expressed by naive and T reg CD4 + T cells show only a minimal overlap, we postulate that T reg subset expressing TCRs shared with naive cells represents adaptive T reg cells [20] [21] [22] . Our findings corroborated recent report showing that two subsets of peripheral T reg cells exist in mice not subject to any deliberate antigen stimulation [23] .
The heterogeneity of T reg population was also described in humans. Two functional subsets of Foxp3
+ T reg cells with distinct capacity to secrete IL-10 and TGF-b and using different mechanisms of suppression were defined by expression of ICOS [24] . High levels of ICOS was also expressed on melanoma tumor infiltrating T reg cells producing high level of IL-10 [25] lo ) able to produce IL-2 and IFN-c [26] . Resting T reg cells convert into activated T reg cells and the relative proportions of these subsets change in aged and diseased individuals. In summary, both in humans and in mice peripheral T reg cells are heterogenous and include subsets with different phenotypic and functional characteristics that are subject to dynamic regulation. It is not known what is the contribution of the recently identified T reg subsets to the generation of T reg population in cancer, especially to the population of T reg cells in tumor lesions.
While it is well established that upregulation of Foxp3 in effector CD4 + T cells leads to the generation of T reg cells, it is unclear what is the contribution of converted and pre-existing T reg cells to the population of Foxp3 + T cells in tumors [27] . Experiments investigating T reg cells in tumor-bearing mice that used adoptively transferred effector and T reg cells expressing transgenic TCR specific for tumor antigen have found that both subsets contribute to T reg population [28] . However, it is not known how the number of transferred cells affects the recruitment of antigen-specific effector and T reg CD4 + T cells into tumor draining lymph nodes and tumors and if their migration, sensitivity to cytokines and/or conversion into T reg cells is the same as CD4 + T cells that naturally developed in recipient mice. Moreover, since the majority of T reg cells express different TCRs than effector T cells, it is unclear if T reg cells expressing the same transgenic TCR as effector T cells used in these studies are equivalent to the majority of T reg cells present in healthy mice.
To determine the origin of T reg cells in cancer, we used an experimental model in which immune response, of both effector and T reg cells, to tumor-associated antigens can be characterized in mice with a restricted and readily characterized CD4 + T cell repertoire. These mice undergo natural generation of a polyclonal CD4 + T cell repertoire with the set of TCR sequences that are used by the majority of natural T reg cells distinct and readily differentiable from the set of sequences used by effector T cells [22] . This allows us to ask whether tumor-associated T reg cells arise from the repertoire of TCRs used by natural T reg cells or from the repertoire used by effector cells. We show that T reg population in tumors is dominated by T cells expressing the same TCRs as effector T cells. These data suggest that T reg in tumors are generated by expansion of a minor subset of T reg cells that shares TCRs with effector T cells or by conversion of effector CD4
+ T cells and thus could represent adaptive T reg cells. In contrast, we found that pre-existing T reg cells, expressing an exclusive set of TCRs, that dominate in healthy mice constitute only a small proportion of T reg cells in tumors. We also demonstrate that immunotherapy aimed at stimulating immune response does not change proportions of T reg and effector CD4 + T cells in tumor-bearing mice.
Methods

Ethics Statement
Full details of the study and all procedures performed on animals were approved by the Institutional Animal Care and Use Committee of the Medical College of Georgia (approval number 09-06-213) and complied with all state, federal, and NIH regulations.
GFP mice were generated by crossing TCR mini mice expressing restricted TCR repertoire with transgenic mice expressing Foxp3 GFP reporter transgene [20, 22] . TCR mini mice harbor a minirepertoire of TCR a chains encoded by Va2.9 and Ja26 (or Ja2) associated with one rearranged TCR Vb14 chain. The mice were crossed to TCRa chain knockout mice to prevent rearrangements of endogenous TCRa chains. Thus, the diversity of the TCR repertoire depends on the CDR3 region of the TCRa chain. Mice expressing a congenic marker Ly5.1 were purchased form Jackson Laboratory (Bar Harbor, ME) and crossed with transgenic Foxp3 GFP mice. All animals used were on the C57BL6 background. Mice were maintained in a specific pathogen-free conditions in a controlled environment which included filtered air and a 12 hour light/dark cycle. All animals had free access to food and water.
Tumors
The mouse melanoma cell line B16F1 was obtained from ATCC. For most experiments B16 melanoma expressing Ep63K peptide as part of the influenza virus nucleoprotein was used. A DNA fragment encoding Ep63K peptide (17 amino-acids long) was introduced between amino acids 264-280 of the nucleoprotein (gift of Dr. G. Price) using standard molecular biology techniques. Modified nucleoprotein (after removal of a stop codon) was subcloned into pEGFP-N1 vector (EcoRI-SalI sites, SalI site within Ep63K peptide was mutated during cloning process) to tag it with green fluorescent protein (GFP) at the C terminus and then cloned into LZRS-pBMN-Z retroviral vector (between EcoRI and NotI sites). Retroviral particles were generated as described by transfecting the Phoenix 293T packaging cell line, a human embryonic kidney line that produces helper-free ecotropic retroviruses (provided by Dr. G. Nolan). Retrovirally transduced cells expressed NP-Ep63K-GFP complexes for at least three weeks of in vitro culture as assessed by stable GFP expression. To produce tumors, B16 melanoma cells devoid of or expressing NP-Ep63K-GFP were sorted and expanded in vitro for 2-3 days before injection. Tumor cells (5610 4 ) were injected s.c. in the upper, inside of both thighs of 6-8 week old TCR mini -Foxp3 GFP mice and mice were analyzed after indicated time. Lymph nodes from two mice were pooled for TCR repertoire analyzes.
Cell purification, flow cytometry and cell sorting
Single-cell suspensions were prepared from lymph nodes by mechanical disruption and cells were stained with antibodies available commercially (eBioscience or BD Biosciences). Tumor infiltrating lymphocytes (TILs) were prepared from tumor lesions by scrubbing tumor tissue into PBS with 0.1 M EDTA. B16 cell suspension (10 7 cells/ml) was then overlaid on 5 ml of Lympho-lyte-M (Cedarlane, NC) gradient and spun at 23006g for 20 min. at 24uC. The cells at the interphase were collected and, after washing with HBSS, stained with monoclonal antibodies for flow cytometry analysis and sorting. Cells were analyzed using FACSCanto flow cytometer (Becton Dickinson) and FACSDiva or WinList software. Cells were sorted on a MoFlo cell sorter (Cytomation). Purity of sorted populations exceeded 98.5%.
Proliferation assay
Proliferation assays were performed with the population of total CD4 + T cells or CD4
+
Foxp3
GFP-cells sorted from B16 tumors and tumor-draining lymph nodes. TCR mini -Foxp3 GFP mice were inoculated with B16 melanoma expressing NP-Ep63K-GFP construct (5610 4 injected s.c.) and tumors were allowed to grow for 2 weeks. Sorted cells (10 5 /well) were incubated on a 96-well plate with irradiated splenocytes devoid of T cells (10 5 /well, 3000 Rad) and soluble anti-CD3e (5 mg/ml). Proliferation responses were measured by adding 1 mCi/well of Analysis of the TCR repertoire using 2D-F-SSCP analysis was performed on sorted populations of effector and T reg cells from control, tumor draining lymph nodes and tumor tissues of TCR mini -Foxp3 GFP mice injected with melanoma cells as described previously [22] . Tumor cells were injected s.c. in both thighs. For analysis brachial and axillary lymph nodes were considered control lymph nodes, inguinal lymph nodes were tumor draining lymph nodes. The purity of the sorted populations exceeded 98%. cDNA prepared from at least 10 5 sorted cells was used for amplification of the TCRa chains. Fluorescent images were acquired by scanning the slab gel in a Typhoon 9410 imager (Amersham-Pharmacia) and analyzed with Image Master 5.0 Platinum software (Amersham-Pharmacia). DNA gels representing individual cell populations were aligned using control spots of known DNA sequence added to each sample. DNA for control spots was selected such that control spots fall outside the gel area utilized by sample DNA. Spot detection and spot comparison was accomplished automatically by image analysis software. In a few cases spots were manually aligned. + CD25 + T cells were sorted from control, draining lymph nodes and tumors. The purity of the sorted populations exceeded 98%. These populations were subsequently subjected to single-cell sorting as described previously [20] . Cells from two TCR mini -Foxp3 GFP mice were combined for cell sorting. We analyzed 316, 135, 135 TCRs from naive, activated and T reg cells from control lymph nodes and 187, 176 and 136 TCRs from the respective populations isolated from draining lymph nodes. For tumors, 173 and 275 TCRs were analyzed from activated and T reg cells. DNA sequencing was done in the DNA sequencing core facility at the University of Illinois.
Single-cell RT-PCR and TCR sequencing
Cytokine and transcription factor detection by RT-PCR
CD4
+
Foxp3
GFP-and CD4
+
Foxp3
GFP+ T cells were sorted from tumors and RNA was isolated with an RNeasy Mini Kit (Qiagen) and reverse transcribed using a Superscript kit (Invitrogen) according to the manufacturer's instructions. b-actin was used to normalize cDNA quantities and was amplified with the sense primer 59CCTTCTACAATGAGCTGCGTGTGGC39 and antisense primer 59CATGAGGTAGTCTGTCAGGTCC39. Cytokine and Foxp3 cDNA was amplified using the following primers: Foxp3 sense: 59ATCCAGCCTGCCTCTGACAAGAACC39, antisense: 59GGGTTGTCCAGTGGACGCACTTGGAGC39. These primers distinguish between amplification product of the endogenous Foxp3 gene (401 bp) and the transgenic transcript (1357 bp). IL-10, sense: 59AGTGGAGCAGGTGAAGAGTG39, antisense: 59TTC-GGAGAGAGGTACAAACG39, TGF-b sense: 59GCTACCAT-GCCAACTTCTGT39, antisense: 59CGTAGTAGACGATGGG-CAGT39. 
Proliferation inhibition assay
Statistical analysis
Diversity of the TCR repertoires was calculated using the Chao mean estimators of unobserved species with 95% confidence intervals obtained via bootstrap method based on 10,000 resamples [30] . To assess the similarity between the TCR repertoires we have calculated the relative entropy (or KullbackLeibler distance) for each of the cell subsets against the pooled ''superpopulation'' consisting of all receptors and pooled relative frequencies [31] . For a given population repertoire the KullbackLeibler distance against the superpopulation was calculated as the sum of the products between p k and log(p k /q k ) where p k denotes the population frequency of the k-th TCR and q k denotes the pooled frequency of the k-th TCR (i.e., frequency in the superpopulation). The Kullback-Leibler distance from the superpopulation was then bias-corrected by subtracting the estimate of the first order bias given by (Ĵ21)/(2n) where Ĵ is the Chao mean and n is the number of all cells in the given population. The confidence intervals for the bias-corrected Kullback-Leibler distances against superpopulation were calculated using the bootstrap method with 10,000 resamples. All calculation were done using R software package.
Results
B16 melanoma expressing Ep63K peptide as a tumor-associated antigen
We have studied immune response in cancer in TCR mini -
Foxp3
GFP mice using B16 transplantable tumor model [20] . TCR mini mice express a naturally generated, polyclonal TCR repertoire where we can follow the frequency of individual T cell clones in cell subsets defined by expression of the Foxp3 and surface markers [20, 22] . The relative diversities and the size of individual clones of CD4 + T cell subsets in TCR mini mice are similar to the natural TCR repertoire as recently determined by high throughput sequencing of TCRs expressed by human T cells [32] . The Ep63K peptide is a cognate antigen recognized by the rearranged TCR that was used to produce TCR mini mice. The TCRs specific for Ep63K were identified and their frequency is known in unmanipulated TCR mini -Foxp3 GFP mice and in mice undergoing response to antigen following immunization with peptide and CFA (Fig. 1A) [20, 33] . To take advantage of the defined TCR repertoire of Ep63K-specific T cells, B16 melanoma was modified to express this peptide. Since it is generally accepted that tumor tolerance and immunity are induced by crosspresentation of tumor antigens, even for class II MHC positive tumors, we have prepared B16 cells expressing Ep63K peptide as part of the influenza virus nucleoprotein (NP) (Fig. 1B) [34] . During viral infection, NP expressed in cells lacking MHC class II molecules, is processed to peptides p260-283 and p413-435, which bind A b on antigen presenting cells [35] . A DNA fragment encoding Ep63K peptide (17 amino-acids long) was introduced between amino acids 264-280 of the nucleoprotein using standard molecular biology techniques. The amino acids flanking mutant peptide p260-283 were preserved in the modified nucleoprotein to ensure proper proteolytic processing of NP-Ep63K. Modified protein was tagged with green fluorescent protein and expressed in B16 melanoma (Fig. 1C) . Cross-presentation and processing of modified nucleoprotein was tested by stimulating Ep63K-specific hybridoma 123.3 with recombinant NP-Ep63K (Fig. 1D ) [36] .
Ep63K peptide generated by processing of modified NP represents antigenic epitope for which immune system is not tolerant. This class of tumor-associated antigens could potentially induce more robust immune response than antigenic epitopes generated by processing of natural, unmutated self proteins and offers best potential for successful immunotherapy. Recent reports show remarkable accumulation of mutations by tumor-associated antigens, including proteins that contribute to the neoplastic process [37] . Mutant proteins are a source of novel and unique antigenic epitopes and demonstrate that tumor cells themselves are a source of a polyvalent vaccine [38] . These new findings suggest that appropriate manipulation of the immune system could offer an opportunity to exploit the immunogenicity of the tumors for cancer immunotherapy.
Analysis of the TCR repertoire in TCR mini -Foxp3 GFP mice bearing late stage melanoma tumors reveals expansion of antigen-specific effector and regulatory CD4 + T cells
To investigate how populations of CD4 + effector and T reg cells change during immune response in cancer and how these two T cell subsets contribute to the T cell population in the tumordraining lymph nodes and tumor tissue, we have followed immune response to transplantable B16 melanoma. T reg cells are known to promote growth of B16 melanoma by inhibiting immune responses to melanoma-associated antigens [12] . B16 melanoma expressing NP-Ep63K was inoculated into TCR mini -Foxp3 GFP mice and CD4 + T cell populations were analyzed in the control and tumor-draining lymph nodes and tumors 19 days after tumor inoculation. Flow cytometry analysis shows increased proportion of activated cells in the draining lymph nodes and tumors consistent with the ongoing immune response ( Fig. 2A) . Increased proportion of activated T cells is however paralleled by the concomitant increase of the Foxp3 + T reg cells. CD4 + Foxp3 GFP+ cells in the tumor draining lymph nodes and tumors express higher levels of CTLA-4 and GITR than activated Foxp3 GFP-cells (Fig. 2B) . These cells express Foxp3 and high levels of IL-10 and TGF-b, cytokines known to contribute to the suppressor function of T reg cells (Fig. 2C) . Foxp3 GFP+ cells sorted from B16 tumors are able to suppress proliferation of effector CD4 + T cells in vitro (Fig. 2D ). In conclusion, phenotypic and functional analyzes strongly suggest that CD4 +   Foxp3 GFP+ T cells that develop in melanoma tumors represent genuine T reg cells and not cells that transiently upregulate Foxp3 without acquiring suppressor function [39] .
To determine the diversity of CD4 + T cell subsets and assess the abundance of individual T cell clones, we have used twodimensional, fluorescent, single-stranded conformational polymorphism (2D-F-SSCP) analysis [22] . TCRa chains were amplified from naive CD44 + cells sorted from control and draining lymph nodes and tumor infiltrate (Fig. 3) . We have divided T reg population into cells expressing high and low level of the Foxp3 GFP reporter since they constitute functionally different T reg subsets in unmanipulated mice [20] . Fluorescent PCR products of TCRa chains were first separated according to their length and subsequently according to their nucleotide sequence. DNA gels representing individual cell populations were aligned using control spots and pair wise comparison of gel images was accomplished by analysis software. The similarity of TCR repertoires was assessed by counting the numbers of overlapping DNA spots. As shown in Fig. 3 , the gels representing the TCR repertoires of naive cells in the control and the draining lymph nodes are very similar (72.9% of overlapping spots) since T cell clones in these subsets are not subject to antigendriven selection and expansion. In contrast, the TCR repertoires of activated and Foxp3
GFPlo and Foxp3 GFPhi T reg cells show various degree of similarity between anatomical locations. Analysis of the overlapping spots shows that populations of activated cells in the draining lymph nodes and tumors are very similar while they differ from the corresponding population in the control lymph nodes. Similar relationship was observed for Foxp3
GFPlo and Foxp3
GFPhi subsets. The TCR repertoires of Foxp3 GFPlo and Foxp3
GFPhi cells from tumors were more similar to the repertoires of the respective T reg populations in the draining lymph nodes than in control lymph nodes. In addition, the TCR repertoires of activated T cells and Foxp3
GFPlo and Foxp3 GFPhi subsets are more similar in tumor draining lymph nodes and tumors than in the control lymph nodes. This suggests that T cell clones from effector cells are recruited into T reg population in tumor draining lymph nodes and tumors. To confirm that clones expanded in T reg populations express the same TCRs as activated T cells, we have isolated and sequenced spot DNA. The spots corresponding to the most prominent Ep63K-specific clone are shown on the gel image representing a population of T reg cells in tumor tissue (Fig. 3A) . In summary, analysis of gel images reveals changes of TCR repertoires characteristic of the ongoing clonal selection and expansion and suggests that immune response to tumorderived antigens resembles response to conventional antigen stimulation [40] .
Tumor antigen-specific T cell clones expressing the same TCRs are concurrently expanded in effector and T reg subsets in the draining lymph nodes and tumor tissue GFP+ T reg cells from control and draining lymph nodes and TILs and by sequencing TCRa chain genes [20, 22] . Naive population was not sorted from tumor tissue since almost all cells expressed an activated phenotype. The diversity of TCRs within populations and the overlap between populations were assessed using Chao mean and relative entropy index respectively (Fig. 4A, B) [20, 22] . The TCR diversity of naive and activated CD4
+ T cells increased in tumor draining lymph nodes in comparison to control lymph nodes and decreased in tumor tissue. Increased diversity in the draining lymph nodes may reflect recruitment and expansion of T cell clones associated with inflammatory response in the neighboring tissues. Further clonal expansion and selection occurred in tumor tissue and resulted in decreased diversity of the TCR repertoire. Diversity of TCRs expressed by T reg cells was highest in control lymph nodes, not subject to antigen stimulation (consistent with the analysis of unmanipulated mice), and decreased in tumor draining lymph nodes and in tumors. This suggests that T reg cells are subject to the most prominent constriction of the TCR repertoire and further implies that many TCRs expressed in control lymph nodes (and in healthy mice) will not be present in tumors (Fig. 4A) . Analysis of the TCR repertoire overlap was conducted to reveal relationship between T cell populations. This analysis shows that T reg cells in control lymph nodes, that mostly resemble T reg population in unmanipulated mice, express most divergent TCR repertoire from all other T cell subsets. In contrast, T reg cells in tumors and tumor draining lymph nodes are more similar to activated T cell subsets from the respective anatomic locations. This suggests that these T reg subsets include higher proportion of cells expressing the same TCRs as activated cells. TCR repertoires of activated T cells in control lymph nodes express intermediate TCR repertoire between activated and T reg cells from tumor draining lymph nodes and tumors and naive cells. Both naive cell populations in control and draining lymph nodes are similar, consistent with the lack of antigen mediated selection (Fig. 4B) . In conclusions, statistical analysis conducted on TCRs indicates close relationship between activated and T reg cells in tumor draining lymph nodes and tumors, significant divergence of T reg cells in control lymph nodes from all other T cell subsets and close similarity of naive cells in control and tumor draining lymph nodes.
To examine cellular processes in cancer immune response, we followed individual T cell clones in populations of naive, activated and T reg cells in control and draining lymph nodes and in tumors. Naive cells in control lymph nodes were least affected by the ongoing anti-tumor response. Single-cell analysis shows a + T cells in control lymph nodes of tumorbearing mice, 16 were also most abundant in naive cells of unmanipulated mice (Fig. 5A) . T cells expressing these receptors constituted 69.0 and 70.0% of the respective naive populations.
Similar comparison between the 20 most abundant clones of naive cells in control and the draining lymph nodes of tumor-bearing mice shows that only 10 clones were the same in the later population and they amounted to only 43.3% of all naive cells (Fig. 5B) . Differences in the TCR repertoires of naive T cells in control and draining lymph nodes are most likely caused by recruitment of antigen-specific naive cells into draining lymph nodes before they acquire activation markers.
In contrast to the population of naive cells, TCR repertoires of activated cells show more pronounced differences between anatomical locations. Analysis of the twenty most abundant T cell clones in tumor tissue shows that they account for about 60.0% of activated TILs (Fig. 5C) . Six of these clones were also found in the tumor draining lymph nodes (13.0% of activated T cells) and fourteen were found in control lymph nodes (20.7% of activated cells). Thus, not all T cell clones predominating in the tumors are also present in the tumor draining lymph nodes suggesting that some tumor-specific T cells may migrate directly to tumors. The same T cell clones accounted for 2.9% of all T reg cells in the control lymph nodes, 11.0% of T reg cells in the draining lymph nodes and 49.5% of T reg cells in the tumor tissue. This shows increased contribution of effector T cells to the population of T reg cells. This process is well exemplified by Ep63K-specific T cells (Fig. 6) . The distribution of cells between the populations of activated and T reg cells varied for individual Ep63K-specific T cell clones. Three clones (#26, 31, 36) frequently found in control lymph nodes were also found in the draining lymph nodes, however we did not observe their clonal expansion. These clones were also found abundant in unmanipulated mice and did not expand upon immunization with Ep63K-peptide and CFA [20] . Only one of these clones (#36) was found expanded in tumors mainly in the population of activated T cells. While two clones dominate immune response to Ep63K peptide and CFA (#274 and 7), in tumor-bearing mice only one clone (#274) was abundant in B16 tumors expressing NP-Ep63K [20] . This might be caused by the differences in the conformation of Ep63K epitope when it is presented as a soluble peptide or processed from NPEp63K protein. Since clone #274 was also found in B16 tumors not expressing Ep63K (see below), it is likely that its expansion in modified tumors resulted from the recognition of both Ep63K and a natural, unknown epitope produced by melanoma cells. Clone #274 constituted 5.7 and 0.7% of activated and T reg cells in draining lymph nodes and 2.9 and 14.9% of activated and T reg cells in tumors. Thus, this clone is a good example of a major functional change experienced by effector CD4 + T cells and while it constituted about 90.0% of activated and 10.0% of Ep63K-specific T reg cells in the draining lymph nodes, in tumors it accounted for only 15.0% of activated and 76.0% of Ep63K-specific T reg cells. In summary, TCR repertoire analysis suggests efficient recruitment of tumor-antigen specific cells into tumor lesions and tumor draining lymph nodes. The initial encounter with tumor derived antigens most likely occurs in the tumordraining lymph nodes where specific clones were first found expanded. Further expansion occurring in the tumor is associated with induction of the Foxp3 expression and acquisition of the suppressor phenotype. Increased contribution of Ep63K-specific clones to the population of T reg cells in tumors is paralleled by other CD4 + T cell clones dominating the population of activated CD4 + T cells in tumors. These clones constitute 41.0, 6.7 and 
12.6% of activated CD4
+ T cells and 29.9, 4.7 and 0% of T reg cells in tumors, tumor draining lymph nodes and control lymph nodes respectively. Ten TCRs (marked with x) of the twenty that dominate the population of activated TILs were also found in the population of CD4 +
CD25
+ cells isolated from B16 tumors not expressing Ep63K epitope (Fig. 5C ). Due to limited sampling, the TCRs we found in B16 tumors expressing and devoid of Ep63K likely represent only partial overlap of the TCR repertoires. Thus, analysis of the TCR repertoires of activated and T reg cells in various anatomic locations shows that both tumor neo-antigen and natural B16-associated antigens shape the repertoires of CD4 + T cell subsets. In conclusion, activation/expansion of effector CD4 + T cells is associated with the increased proportion of T reg cells expressing TCRs shared with effector cells in tumors.
We have established that T reg cells expressing TCRs shared with effector CD4 + T cells constitute about half of all T reg cells in the tumor site while in unmanipulated mice they account for only 10-15% of all T reg cells (Fig. 5C ) [20] . Most T reg cells in normal mice, not subjected to antigen stimulation express an exclusive set of TCRs, different from TCRs expressed by effector T cells, so it was important to determine the contribution of this subset to the T reg population in tumors. We have selected twenty T reg clones most abundant in tumors (account for 72.4% of all T reg cells) and using our database of TCR sequences collected from unmanipulated and tumor-bearing mice identified clones that express TCRs shared with naive T cells and TCRs unique for the T reg cells (Fig. 5D) . We found that eleven TCRs expressed by 38.9% of all T reg cells were also expressed by naive cells and only one TCR (expressed by 1.1% of T reg cells) was found solely in T reg subset. Other receptors were not found in the database. The same analysis conducted on eight T reg clones, with unknown antigen specificity, shows that TCRs shared with effector CD4 + T cells (receptor sequences depicted in black and labeled with N) constitute 18.2% and 3.7% of all T reg cells in tumors and tumor draining lymph nodes respectively and are not found in the control lymph nodes. In summary, T reg cells expressing TCRs shared with effector cells constitute an increasing proportion of all T reg cells and contribute to the TCR diversity of these cells.
To further investigate composition of T reg subsets in tumors, we looked at T reg clones expressing twenty most frequent TCRs exclusive for T reg cells (Fig. 5E ). This set of TCRs accounted for 25.7% of all T reg cells in lymph nodes of unmanipulated mice, 26.0% of T reg cells in the draining lymph nodes of tumor-bearing mice (10 TCRs found) and for only 2.6% of all T reg cells in tumors (7 of these TCRs were found). Extending this analysis to all T regspecific TCRs, we found that of 79 unique TCRs found in tumordraining lymph nodes 48 TCRs belonged to a TCR subset found exclusively in T reg cells while of 91 unique TCRs found in tumors only 2 TCRs belonged to this cell subset despite sequencing twice more receptors from tumor tissue. This surprising result suggests that T reg cells expressing a unique set of TCRs and predominating in normal mice have different behavior than T reg cells expressing TCRs shared with effector T cells present in tumor-bearing mice. In addition, the most abundant T reg clone expressing a TCR found only in T reg cells accounted for 1.1% of all T reg cells in tumors. While we do not know why T reg cells expressing an exclusive set of TCRs are underrepresented in the tumor infiltrate with regard to both clonal abundance and TCR diversity, possible reasons include impaired migration to tumors, inferior expansion and/or very low frequency of these cells in mice before tumor GFP-cells that acquire Foxp3 expression represent adaptive T reg cells generated in response to self peptides or antigens derived from commensal flora [20, 41] . Figure 7 shows analysis of recipient mice that received populations of CD4 GFPhi cells represented 9.5% of transferred cells and accounted for 31.2% of all T reg cells in lymph nodes of recipient mice (Fig. 7A) . However, the same cells in the tumors represented only 2.3% of all transferred cells and 4.8% of T reg cells (Fig. 7B) . This low proportion of T reg cells in tumors originating from the preexisting Foxp3 + cells is a consequence of superior recruitment/expansion of CD4 + Foxp3 GFP-cells in the tumor tissue with simultaneous increase in the proportion of Foxp3 GFP+ T cells in this subset. This outcome is consistent with recent reports that the population of T reg cells exhibiting a flexible phenotype and expressing TCRs shared with effector cells (and representing adaptive T reg cells) expands much better in response to antigen stimulation or in lymphopenic mice than T reg cells expressing an exclusive set of TCRs that are found in Foxp3 GFPhi population sorted from unmanipulated mice [20, 23] . Increased proportion of T reg cells in melanoma tumors than in peripheral blood and peritumoral tissue was also reported in melanoma patients and was attributed to selective migration and/or expansion of T reg cells in tumors [42] . Both Ep63K-specific CD4 + T cells and effector cells with unknown antigen specificity present in the TCR mini mice as well as adaptively transferred CD4 + Foxp3 GFP-cells expressing a wild type diversity of the TCR repertoire were found dominating the population of T reg cells in melanoma tumors. In conclusion, inherent properties of T reg cells expressing TCRs shared with naive T cells like efficient recruitment, expansion and/or upregulation of Foxp3 are responsible for the predominance of adaptive T reg cells in tumors.
Immunotherapy with dendritic cells presenting tumor-associated antigen fails to prevent generation of adaptive T reg cells in tumor tissue
We reasoned that the overwhelming presence of adaptive T reg cells in tumors might be caused by suboptimal antigen stimulation in tumors compared to draining lymph nodes and could be corrected by immunotherapy. Previous reports showed that stimulation with limited antigen dose and premature termination of TCR signaling promotes generation of T reg cells [43, 44] . To improve the ratio of effector and T reg cells, we augmented immune response to tumor-associated antigen using dendritic cells.
C57BL6 Foxp3
GFP mice (expressing wild type TCR repertoire) were inoculated with B16 melanoma expressing NP-Ep63K. Bone marrow-derived dendritic cells expressing covalently bound complex of A b Ep63K complex were co-injected in the same site at the time of tumor inoculation [33] . Injections of dendritic cell continued daily until mice were sacrificed. GFP mice in vitro or in vivo without significant increase in the proportion of T reg cells (Fig. 8A) . Tumor-bearing mice were sacrificed after two weeks and T cells from control and draining lymph nodes and tumor tissue were analyzed by flow cytometry (Fig. 8B) . Mice undergoing dendritic cell therapy had more CD4
+ T cells in tumor-draining lymph nodes and tumors and a higher fraction of CD4 + T cells expressed an activated phenotype what shows that dendritic cells were effectively stimulating Ep63K-specific T cells. However, augmented activation of effector CD4 + T cells was accompanied by the concomitant increase in the fraction of T reg cells. In conclusion, stimulation of tumor antigen-specific effector cells is associated with conversion and/or expansion of T reg cells specific for the same antigen. This finding suggests that efficient presentation of antigen might not be sufficient to favor the generation of activated T cells in the context of tumor microenvironment.
Discussion
Emerging data suggest that the population of Foxp3 + T reg cells is heterogeneous in humans and mice in terms of its origin and functional properties [19, 20, 24, 26] . However, since the expression of the cell surface markers may change reflecting different activation or functional status of a T reg cell, it might be difficult to follow T reg subsets in the course of immune response. In a recent report we were able to correlate functional phenotype of T reg cells with the expression of a TCR [20] . Thus, we could use the analysis of the TCR repertoire in TCR mini -Foxp3 GFP mice to determine the origin and abundance of T reg subsets expressing TCRs shared with effector T cells and expressing an exclusive set of TCRs.
Despite recent advances in immunotherapy, T reg cells remain the major obstacle for successful cancer treatment. It is therefore important to determine what is the source and cellular composition of T reg cells in tumors. We investigated T reg population in tumor-bearing TCR mini -Foxp3 GFP mice expressing naturally rearranged, polyclonal TCR repertoire. To our knowl-edge this is the first model that allows for comprehensive assessment how the origin and antigenic specificity of T cell populations change in the course of tumor development. Considering the major impact of T reg cells on cancer pathology, we have investigated the origin of these cells, anatomical location where tumor specific T reg cells are first detectable and the stage of tumor growth when they are first expanded.
To follow tumor antigen-specific CD4 + T cells, B16 melanoma was modified to express NP-Ep63K recombinant protein.
Processing of the recombinant protein by antigen presenting cells generates Ep63K epitope that mimics tumor associated antigens that arise from mutant, endogenous proteins for which immune system is not tolerant but which were proposed to be the most efficient targets for immunotherapy [37, 38, 46] . The inclusion of an experimental neoantigen was dictated by multiple reports showing that tumors naturally produce antigenic epitopes derived from mutant as well as native proteins. These antigenic epitopes are able to elicit activation, clonal expansion and acquisition of effector functions by antigen specific cytotoxic and helper CD4 + T cells [47] [48] [49] [50] [51] . In conclusion, by using tumor cells expressing a neoantigen, we facilitate studies how cellular mechanisms are established that protect tumors from the immune system and result in the induction of an active tolerance/anergy mediated by T reg cells [14, 52] .
Analysis of the TCR repertoires in TCR mini -Foxp3 GFP mice bearing B16 tumors expressing NP-Ep63K demonstrates that the population of T reg cells expressing TCRs shared with naive CD4 + T cells, and not the T reg cells expressing an exclusive set of TCRs, constitute a majority of Foxp3 + T reg cells in tumors. The recent report and our own data show that the population of peripheral Foxp3
+ T reg cells in unmanipulated mice is heterogeneous and includes a subset expressing TCRs shared with effector T cells [20, 23] . Thus, it is not possible to demonstrate whether an individual T reg cell expressing a shared TCR in tumor-bearing mice arose from expansion of a cell preexisting in a healthy mouse, or from an effector T cell converted during tumor antigen-driven response and thus representing an adaptive T reg cell. This distinction may not be very meaningful since we have recently showed that T reg cells in healthy mice expressing shared receptors resemble adaptive T reg cells [20] . At the population level, most likely, both expansion of the preexisting T reg cells expressing shared TCRs and antigen-driven conversion contribute to the abundance of the T reg subset expressing TCRs shared with effector cells. Considering the large size of the population of naive CD4 + T cells and a comparably small proportion of T reg cells expressing shared TCRs, most of T reg cells in tumors are likely generated by conversion of effector CD4 + T cells. This view is supported by evidence of efficient expansion of the preexisting adaptive T reg cells in immunized mice, adaptive transfer studies and by published report demonstrating that conversion into T reg cells is an efficient mechanism of acquiring Foxp3 expression [53, 54] .
Conversion and/or expansion of the T reg cells expressing shared TCRs might be a general feature of response to antigen since these cells were also demonstrated in the draining lymph nodes of mice immunized with peptide antigen and CFA [20] . Thus, regardless of the origin of antigen and possible differences in the mode of antigen presentation, adaptive T reg cells are generated both in immunized and tumor-bearing mice. Inflammation caused by immunization with CFA did not prevent the generation of adaptive T reg cells. In fact, inflammation was found to be a contributing factor in many cancers and our data imply that cancer treatments aimed at stimulating inflammatory reaction in the site of tumor growth may not promote tumor eradication [55] .
Analysis of the frequency of individual Ep63K-specific clones reveals that the magnitude of clonal expansion might correlate with the proportion of T cells that acquire Foxp3 expression and become T reg cells. The major increase in the abundance of antigen-specific cells occurred for T cells expressing TCRs of hybridoma #274 that is rarely found in unmanipulated mice but dominates antigen response to conventional immunization with peptide antigen and CFA. Another Ep63K-specific clone expressing TCR of hybridoma #36 was found modestly expanded in tumors though it was not expanded upon immunization with Ep63K-peptide and CFA [20] . In contrast, CD4 + T cells expressing TCRs utilized by hybridomas #31 and 26 were not expanded in tumor draining lymph nodes and tumors. This is most likely caused by their low affinity for Ep63K since the same cells also did not respond to immunization with soluble Ep63K administered with CFA. Analysis of clonal frequencies in tumors shows that clone #274, that expanded the most, had highest contribution to the T reg population, clone #36, that expanded less, had smaller contribution and clones #31 and #26, that did not expand, were rarely seen in activated and T reg cells in tumors. The association between antigen-driven clonal expansion and acquisition of T reg phenotype was seen in cervical cancer patients and in tumor-bearing mice following vaccination suggesting that it is likely a general phenomenon associated with antigen stimulation [56, 57] . However, previous studies in a mouse model have relied on TCR-transgenic T cells that may not reflect the behavior of a naturally-diverse polyclonal TCR repertoire.
Ep63K-specific CD4 + T cells undergo efficient clonal expansion in response to antigen produced by tumor cells. This experimental system mimics the desired response of the immune system to tumor associated antigen. Some natural tumor antigens, produced at lower levels or less immunogenic, may not elicit efficient cellular response. Our data strongly suggest that immunotherapy targeting this type of antigens by augmenting their antigenicity will have a similar outcome as the response to a highly immunogenic antigens. Activation and clonal expansion of effector CD4
+ T cells will result in the generation of adaptive T reg cells and/or expansion of T reg cells sharing TCR with effector T cells.
The small contribution of T reg cells (both in terms of TCR diversity and clonal abundance) expressing an exclusive set of TCRs and preexisting in healthy mice to the population of Foxp3 + T cells in tumors is surprising, especially considering that these cells still constitute a significant proportion of Foxp3 + T reg cells in the tumor draining lymph nodes. We do not think it is an artifact of our experimental approach. Our conclusions are based on the analysis of single cells that avoids bias that might be introduced by sequencing TCRs from the library amplified by the PCR. In addition, analysis of the clonal abundance accounts for over 70% of all Foxp3 + T cells in tumor tissues so it is unlikely that we missed some T reg clones that account for a large fraction of Foxp3
+ cells in tumors. T reg cells in unmanipulated mice (expressing mainly an exclusive set of TCRs) consistently had the most diverse TCR repertoire in several unmanipulated mice analyzed so far, so it is unlikely that they do not contain tumor-antigen specific cells. We hypothesize that migration or tissue homing of these cells may be different from the majority of T reg cells found in tumors. This interpretation is further supported by the demonstration that T reg cells expressing an exclusive set of TCRs constitute a significant fraction of T reg cells in the tumor draining lymph nodes and by the adaptive transfer experiment showing that T reg cells derived from transferred effector cells are more efficiently recruited and expanded in the tumors than T reg cells preexisting in unmanipulated mice. In fact, recent transcriptional analysis of tumorderived T reg cells shows that they express a different gene expression profile than T reg cells in healthy mice [58] .
Analysis of early and late stage tumors shows that composition of the cellular infiltrate does not change with tumor progression. In contrast, our data show that, at least for the widely used transplantable tumor model, cellular changes that compromise the functions of the immune system do not occur following productive immune response but are evident already at the stage when tumors are first detectable. Tumor models that progress through the salient period of preclinical cancer are needed to investigate how immune response evolves in more natural cancer models but some preliminary data indicate that it may also be compromised at the very early stages of cancer [59] . In fact, recent report demonstrates that T reg cells expand dynamically upon tumor antigen recognition and create tolerogenic environment in tumors from the onset of tumor growth [60] . Though, the analysis of the TCR repertoire of expanded T reg cells was not conducted in this study, it was shown that at least some T reg cells expressed the same TCRs as effector T cells.
Our analysis of the immune response in cancer and previously reported analysis of immune response to peptide antigen administered with strong adjuvant reveals several common features [20] . In both cases antigen-specific effector T cells are efficiently recruited into draining lymph nodes and undergo clonal expansion. Thus, impaired clonal expansion or lack of it is an unlikely cause of the failed response in cancer. Another common feature is that T reg population becomes enriched in cells expressing TCRs shared with effector cells, either by upregulation of Foxp3 in effector T cells, or by expansion of a minor T reg subset. Generation of T reg cells that share TCRs with effector T cells is not a result of suboptimal stimulation by antigen. In contrast, augmenting immunization with professional antigen presenting cells increases generation of both antigen-specific effector and adaptive T reg cells.
In our model, we show that some adaptive T reg cells can be generated in the course of a productive immune response, against antigens presented via conventional immunization. This process enriches T reg population in cells with the same antigen specificity as effector cells and would be consistent with the known role of induced T reg responses in limiting excessive inflammation and tissue damage [61] . In the case of tumors, it appears that the natural mechanisms existing to generate or expand T reg cells during response to conventional antigen become exaggerated and subverted by tumor cells. This elicits disproportionate production of T reg cells and shifts the cellular balance from effector helper cells towards cells with suppressor function in order to avoid immune system mediated destruction. The outcome of immunization with dendritic cells expressing the same antigen as tumor cells demonstrates that even strong stimulation with antigen in the tumor site still does not shift the balance to favor production of effector T cells at the expense of T reg cells. This further suggests that improved cancer immunotherapy may depend on the ability to block tumor-antigen induced expansion of a minor T reg subset or generation of adaptive T reg cells, rather than solely on increasing the immunogenicity of vaccines.
